Monday, August 16, 2010

Solstice Neurosciences Acquired

Solstice Neurosciences, a firm which as its production and manufacturing in San Francisco, but is based out of Malvern, PA, has been acquired. According to Kentucky-based US Worldmeds, it has acquired Solstice Neuroscience for $35M. US Worldmeds said the acquisition expands its operations and add to its portfolio of products. Solstice was backed by Highland Capital, Investor Growth Capital Ltd., Morgan Stanley, Oxford Bioscience Partners, and Thomas, McNerney & Partners, and had raised over $93M in funding. Solstice Neurosciences develops MYOBLOC (rimabotulinumtoxinB) and NeuroBloc (Botulinum Toxin Type B), which was used for the treatment of cervical dystonia. More information »